The USC/Norris Comprehensive Cancer Center at the University of Southern California was founded in 1971 and has been continuously supported by a Cancer Center Core Support Grant since 1973. It has developed into a major regional and national resource for cancer research, treatment, prevention and education. Center facilities have been built and developed with support from the NCI, the University, and the Kenneth Norris Jr. Cancer Hospital which is an integral part of the Cancer Center. The Center is undergoing a major expansion by the addition of the Norman Topping Tower (110,000 nsf) attached to the existing headquarters building. The Center's research programs are organized into five discipline-based and four disease-based programs. The discipline-based programs are headed by senior investigators in the fields of gene regulation, cell biology, developmental therapeutics and clinical trials, cancer epidemiology and cancer control research. The disease-based programs which provide focus to our multidisciplinary research efforts are in genitourinary, gastrointestinal, breast cancer and hematologic malignancy/retroviral diseases. This application is for: 1) partial salary support for the Center's senior leadership who are responsible for planning and overseeing our research efforts; 2) support for planning and evaluation to keep the Center at the forefront of cancer research; 3) support for the administrative intrastructure of the Center; 4) partial support for the Center's 13 shared resources which facilitate the conduct of our peer-reviewed research; 5) support for developmental funds to help us recruit new investigators in areas we have targeted for expansion and to provide support for pilot projects, specifically designed to stimulate translational research. Continued funding from the Cancer Center Core Support Program will allow us to build on our strengths in molecular genetics, cell biology, cancer treatment (including gene therapy), cancer epidemiology and cancer control and to translate our underlying expertise into strong, peer-reviewed funded research programs focused on cancers of major consequence in this country.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014089-23S1
Application #
2864792
Study Section
Cancer Centers and Research Programs Review Committee (CCRP)
Program Officer
Vembu, Devi
Project Start
1980-04-01
Project End
2000-11-30
Budget Start
1997-12-01
Budget End
1998-11-30
Support Year
23
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Southern California
Department
Biochemistry
Type
Schools of Arts and Sciences
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Zhang, Junjie; Zhao, Jun; Xu, Simin et al. (2018) Species-Specific Deamidation of cGAS by Herpes Simplex Virus UL37 Protein Facilitates Viral Replication. Cell Host Microbe 24:234-248.e5
Eriguchi, Yoshihiro; Nakamura, Kiminori; Yokoi, Yuki et al. (2018) Essential role of IFN-? in T cell-associated intestinal inflammation. JCI Insight 3:
Battaglin, Francesca; Naseem, Madiha; Puccini, Alberto et al. (2018) Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. Cancer Cell Int 18:99
Cobo, Eduardo R; Holani, Ravi; Moreau, France et al. (2018) Entamoeba histolytica Alters ileal Paneth Cell Functions in Intact and Muc2 Mucin Deficiency. Infect Immun :
Suenaga, Mitsukuni; Schirripa, Marta; Cao, Shu et al. (2018) Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Clin Colorectal Cancer 17:e395-e414
Thomas, Nancy E; Edmiston, Sharon N; Orlow, Irene et al. (2018) Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes. J Invest Dermatol 138:2398-2404
Rhie, Suhn Kyong; Yao, Lijun; Luo, Zhifei et al. (2018) ZFX acts as a transcriptional activator in multiple types of human tumors by binding downstream of transcription start sites at the majority of CpG island promoters. Genome Res :
Pinto, Navin; DuBois, Steven G; Marachelian, Araz et al. (2018) Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatr Blood Cancer 65:e27023
Hanna, Diana L; Loupakis, Fotios; Yang, Dongyun et al. (2018) Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. Clin Colorectal Cancer 17:e471-e488
Müller, Fabian; Cunningham, Tyler; Stookey, Stephanie et al. (2018) 5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox. Proc Natl Acad Sci U S A 115:E1867-E1875

Showing the most recent 10 out of 842 publications